Longeveron Inc.

About Longeveron Inc.

Longeveron is a clinical-stage regenerative medicine biotechnology company focused on developing cellular therapies for life-threatening and chronic aging-related conditions. Their mission is to improve healthspan by repairing and regenerating tissue at the site of damage, inflammation, and disease using stem cell therapies.

Products & Services

Laromestrocel (Lomecel-B™):A cellular therapy product being evaluated for treating conditions such as Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's Disease, and Aging Frailty through clinical trials.

CDMO Services:Contract Development and Manufacturing Organization services to support the production of cellular therapies.

Specialties

Stem Cell Therapies Cellular Therapies for Aging-Related Conditions Treatment for Hypoplastic Left Heart Syndrome (HLHS) Treatment for Alzheimer's Disease Treatment for Aging Frailty Healthspan Improvement

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 5000000 MR: - FA: approximately $5.0 million FAN: 5000000	D: 2025-08-11 FD: 2025-08-11	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 17500000 MR: - FA: Up to $17.5 Million FAN: 17500000	D: 2025-08-08 FD: 2025-08-08	1 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 9000000 MR: - FA: 9.0 million FAN: 9000000	D: 2024-07-19 FD: 2024-07-19	-
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 9000000 MR: - FA: $9.0 million FAN: 9000000	D: 2024-07-18 FD: 2024-07-18	1 investors
5	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4400000 MR: - FA: 4.4 million FAN: 4400000	D: 2024-06-18 FD: 2024-06-18	-
6	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4400000 MR: - FA: 4.4 million FAN: 4400000	D: 2024-06-17 FD: 2024-06-17	1 investors
7	RT: Warrant Exercise and Public Offering T: - FT: Warrant Exercise and Public Offering	A: 11400000 MR: - FA: $11.4 million FAN: 11400000	D: 2024-04-18 FD: 2024-04-18	-
8	RT: Private Placement T: - FT: Private Placement	A: 6200000 MR: - FA: 6.2 million FAN: 6200000	D: 2024-04-17 FD: 2024-04-17	-
9	RT: Public Offering T: - FT: Public Offering	A: 5200000 MR: - FA: $5.2 million FAN: 5200000	D: 2024-04-11 FD: 2024-04-11	2 investors
10	RT: Public Offering T: - FT: Public Offering	A: 5250000 MR: - FA: $5.25 million FAN: 5250000	D: 2024-04-08 FD: 2024-04-08	2 investors
11	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2360000 MR: - FA: 2.36 million FAN: 2360000	D: 2023-12-22 FD: 2023-12-22	-
12	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2360000 MR: - FA: $2.36 million FAN: 2360000	D: 2023-12-21 FD: 2023-12-21	1 investors
13	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4000000 MR: - FA: approximately $4 million FAN: 4000000	D: 2023-10-13 FD: 2023-10-13	-
14	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4000000 MR: - FA: $4 million FAN: 4000000	D: 2023-10-12 FD: 2023-10-12	-
15	RT: Rights Offering T: - FT: Rights Offering	A: 3 MR: - FA: $3.00 FAN: 3	D: 2023-08-22 FD: 2023-08-22	-
16	RT: Rights Offering T: - FT: Rights Offering	A: 3 MR: - FA: $3.00 per share FAN: 3	D: 2023-08-16 FD: 2023-08-16	-
17	RT: Rights Offering T: - FT: Rights Offering	A: 3 MR: - FA: 3.00 FAN: 3	D: 2023-08-14 FD: 2023-08-14	-
18	RT: Rights Offering T: - FT: Rights Offering	A: 30000000 MR: - FA: up to $30,000,000 FAN: 30000000	D: 2023-06-27 FD: 2023-06-27	-

Public Offering Latest

2025-08-11

$5.0M

1 investor (Pro only)

Public Offering 2025-08-08

$17.5M

Registered Direct Offering 2024-07-19

$9.0M

View 17 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jeremy D. Walston, MD

Raymond and Anna Lublin Professor of Geriatric Medicine and Gerontology

E

ELENA VOLPI, MD, Ph.D.

Daisy Emery Allen Distinguished Chair in Geriatric Medicine; Director, Sealy Center on Aging; Director, UTMB Claude D. Pepper Older Americans Independence Center; Associate Director, Institute for Translational Sciences; Professor, Departments of Internal Medicine-Geriatrics, Neuroscience and Cell Biology, Nutrition and Metabolism, Graduate School of Biomedical Sciences

J

Joe G. N. Garcia, MD

Pulmonary Physician-Scientist and Merlin K. DuVal, MD Endowed Professor of Medicine

H

HIDENORI ARAI, MD, Ph.D.

President of the National Center for Geriatrics and Gerontology

J

Joshua M. Hare

Co-Founder, Chief Science Officer and Chairman

D

Donald M. Soffer

Co-founder and Board of Directors Member

View 35 more team members with Pro

Unlock Full Team Directory

Recent News

Longeveron Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised